WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective medicines to treat a wide range of cancers, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2018 BIO International Convention occurring June 4-7, 2018 in Boston, MA. The presentation will take place on Tuesday, June 5, 2018 at 11:00 AM ET in Theatre 1 within the Boston Convention & Exhibition Center.
Mr. Fromkin will provide an overview of the company’s Pentarin platform with a focus on its clinical stage drug candidates, PEN-221 and PEN-866. PEN-221 is currently being studied in the Phase 2a portion of a Phase 1/2a trial in patients with small cell lung cancer as well as GI-midgut and pancreatic neuroendocrine tumors that express somatostatin receptor 2 (SSTR2). PEN-866 recently entered into the Phase 1 portion of a Phase 1/2a trial to assess safety and efficacy across a range of tumor types.
To schedule a meeting with Tarveda’s management team at the Convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact email@example.com.
Tarveda is developing Pentarins™, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new class of potent and selective miniature drug conjugates with enhanced targeting capabilities for the treatment of a wide range of solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniature drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine, small cell lung, prostate, and other cancers that express SSTR2. PEN-221 comprises a highly selective peptide for SSTR2 conjugated to the potent cytotoxic payload, DM1, through a tuned cleavable linker. Tarveda is also advancing its Pentarin HSP90 drug conjugate platform with lead drug candidate PEN-866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38, the highly potent active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. www.tarveda.com